

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61











